Mazyar Shadman, MD, Oncology, Seattle, WA, Seattle Cancer Care Alliance

MazyarShadmanMDMPH

Oncology Seattle, WA

Hematologic Oncology

Assistant Professor of Medicine - Medical Oncology - University of Washington

Overview

Dr. Mazyar Shadman is an oncologist in Seattle, WA and is affiliated with multiple hospitals in the area, including Seattle Cancer Care Alliance and University of Washington Medical Center. He received his medical degree from Tehran University of Medical Sciences School of Medicine and has been in practice 13 years. He is one of 145 doctors at Seattle Cancer Care Alliance and one of 136 doctors at University of Washington Medical Center who specialize in Oncology.

Office Address

Education & Training

  • University of WashingtonUniversity of WashingtonFellowship
  • Cleveland Clinic FoundationCleveland Clinic FoundationResidency
  • University of Washington University of Washington OtherTraining
  • Tehran University of Medical Sciences School of MedicineTehran University of Medical Sciences School of MedicineMedicalSchool

Certifications & Licensure

  • WA State Medical LicenseWA State Medical License 2011 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Trainee Research Award American Society of Hematology (ASH)

Clinical Trials

Publications & Presentations

  • Abstracts/Posters
  • High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Resu... Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • 12 more in this section...Join now to see the full profile
  • Lectures
  • CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas 61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes 61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study 61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • 6 more in this section...Join now to see the full profile

Press Mentions

  • Seattle Cancer Care Alliance At
  • Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and MoreNovember 21, 2019
  • Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual MeetingNovember 06, 2019

Professional Memberships

Hospital Affiliations